Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Anti-Cancer Immunotherapy: Anti-Tumor Vaccines
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
Novel peptide sequences identified from breast, prostate, and bladder cancers are utilized as targets for anti-tumor vaccines. Local therapy such as surgical excision or ablation by radiation is a mainstay for the treatment of primary cancer and is......
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

Novel peptide sequences identified from breast, prostate, and bladder cancers are utilized as targets for anti-tumor vaccines.


Local therapy such as surgical excision or ablation by radiation is a mainstay for the treatment of primary cancer and is curative for a percentage of the patients. However, many malignancies will recur locally or at a distant site. Thus, the prevention or cure of metastases represents a major challenge in clinical oncology. The current invention harnesses the immune system to combat cancer by the activation of endogenous T cell response against the tumors and their metastasis and might offer long-term protection against relapse.



Applications


·         Vaccines against various types of cancer.


·         Possible adjuvant therapy for the treatment of tumor metastases.



Advantages


·         Specific tumor associated antigens (TAAs) are discovered using a transgenic mice approach, which is more robust than conventional methods that use CTL lines. 



Technology's Essence


Some of the key factors involved in facilitating specific immunological response against tumors and their metastases are unique tumor associated antigens (TAAs). Most known TAAs are Cytotoxic T Lymphocyte (CTL) epitopes. CTL directed against such antigens constitute powerful effectors of the immune system against tumors or infectious agents. Clinical investigations have focused on generation of anti-tumor CTL responses, by introduction of tumor-specific TAAs as peptide vaccines. The outlined method enables the identification and synthesis of novel vaccines for the prevention and immunotherapy of various types of cancer as was demonstrated in several animal models.



Licensing Status

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION